Nanoviricides, Inc. (NNVC): Free Cash Flow
-$8.54M
Year ended 2025-06-30
-$7.37M
Trailing 12 months to 2026-03-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | -$8.54M | n/m | 2025-09-29, From 2024-07-01 |
| 2024-06-30 | -$6.47M | n/m | 2025-09-29, From 2023-07-01 |
| 2023-06-30 | -$5.82M | n/m | 2024-09-27, From 2022-07-01 |
| 2022-06-30 | -$6.22M | n/m | 2023-10-13, From 2021-07-01 |
| 2021-06-30 | -$8.45M | n/m | 2022-10-13, From 2020-07-01 |
| 2020-06-30 | -$6.67M | n/m | 2021-10-12, From 2019-07-01 |
| 2019-06-30 | -$6.88M | n/m | 2021-10-12, From 2018-07-01 |
| 2018-06-30 | -$8.02M | n/m | 2020-10-13, From 2017-07-01 |
| 2017-06-30 | -$8.06M | n/m | 2019-08-23, From 2016-07-01 |
| 2016-06-30 | -$7.31M | n/m | 2018-10-12, From 2015-07-01 |
| 2015-06-30 | -$12.97M | n/m | 2017-09-28, From 2014-07-01 |
| 2014-06-30 | -$11.56M | n/a | 2016-09-16, From 2013-07-01 |
| No annual figure between 2012-06-30 and 2014-06-30. | |||
| 2012-06-30 | -$4.24M | n/m | 2015-02-23, From 2011-07-01 |
| 2011-06-30 | -$4.66M | n/a | 2013-10-08, From 2010-06-30 |
| 2010-06-30 | -$2.61M | n/a | 2012-10-26, From 2009-07-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Nanoviricides, Inc. (NNVC) | 2025-06-30 | -$8.54M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $7.39B | +16.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $12.85B | -7.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $9.07B | -7.7% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.70B | -0.7% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $28.84M | +101.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $12.36B | -31.7% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$15.98M | n/m |
| Procyon Corp (PCYN) | 2024-06-30 | -$125.2K | n/m |
Compare NNVC, ABT, BMY, PFE side by side · Screen every company in Pharmaceutical Preparations ↗